Calamos Advisors
ALNY icon

Calamos Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Calamos Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$398K – 1199
2025
Q4 		$398K Sell
1,000
-200
-17% -$88.5K ﹤0.01% 790
2025
Q3 		$547K Buy
+1,200
New +$489K ﹤0.01% 765
2020
Q3 		– Sell
-11,660
Closed -$1.73M – 706
2020
Q2 		$1.73M Buy
+11,660
New +$1.57M 0.01% 591

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Calamos Advisors's ALNY Position: Q1 2026 in Review

Calamos Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,000 shares — an estimated $398K sold.

Calamos Advisors first reported a position in ALNY in Q2 2020 and held it in 3 quarters. The position peaked at $1.73M in Q2 2020. 789 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Calamos Advisors reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Calamos Advisors sold 1,000 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $398K.
  • Calamos Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Calamos Advisors's Alnylam Pharmaceuticals position peaked at $1.73M in Q2 2020.
  • 789 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.